Speakers - Sachs Associates

Speakers
Alexey Eliseev, Managing Director, Maxwell Biotech
Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the
Massachusetts Institute of Technology. His career includes over 17 years of experience in academia, biotechnology industry
and venture capital.
Dr. Eliseev has been working in the United States and Europe since 1992. Following three years of postdoctoral research in
Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry,
University at Buffalo in 1995 where he was awarded tenure in 2000. In 1999 he co-founded the company Therascope (later
Alantos Pharmaceuticals) with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn. The
company used a novel drug discovery technology developed in several academic labs, including Eliseev’s group in Buffalo.
He joined the company in 2000 and later became Chief Technology Officer of Alantos and President of its US division. Alantos
was acquired by Amgen in 2007 for $300 million.
Over the recent years Alexey was involved in starting several biotech companies as a scientist and entrepreneur, including AC
Immune (Switzerland) and Boston BioCom (US). Alexey has been working with the Russian-based Maxwell Biotech Venture
Fund as its Managing Director since 2009. He is responsible for international activity of the Fund and has managed numerous
deals with portfolio companies in the US and Europe.
Allan Marchington, Partner, Apposite Capital
Allan is a founder and Partner at Apposite Capital a London based healthcare investor. Allan was formerly at Abingworth
management and prior to this was a member of Millennium Pharmaceuticals management team as an Senior Vice President
with responsibility for technology Investments. He also served as Chairman of Millennium Pharmaceuticals in Europe. Allan
joined Millennium following their acquisition in July 2000 of Cambridge Discovery Chemistry, where he was CEO and founder.
Allan began his career as a medicinal chemist at Pfizer Central Research.
Allan is a Board member of the BioIndustry Association, Ambit Biosciences Inc., Ambrx Inc., Anaphore Inc., and Convergence
Pharmaceuticals Ltd.
Dr Andreas Caduff, CEO, BioVoition AG
Andreas was born in 1971 and is a Swiss citizen. He held various positions in the pharmaceutical and medical device
industry. In his previous position he was serving as CTO of Solianis Monitoring AG, a company focusing on noninvasive
glucose monitoring. At Solianis, he orchestrated the overall technology and product development, experimental/clinical
study strategies, regulatory considerations, external technical communication and interaction with the industrial/scientific
community, regulatory bodies as well as the investor’s community. He is an expert in physiological monitoring techniques
and involved physiological/metabolic processes, combining the expertise in various fields relevant to the development,
industrialisation and commercialisation of such technologies. Dr. Caduff is a frequent invited speaker at industrial and
scientific conferences and meetings on physiological monitoring, mobile Health and related subjects. He has innovated
numerous patents and co-authored several dozen scientific publications in peer reviewed journals. He holds a BSc degree
in Chemistry from the University of Applied Science, Winterthur, Switzerland, an MSc degree in Biotechnology and a Ph.D. in
Biophysics from the University of Teesside, UK and the Hebrew University of Jerusalem, Israel.
Anne Altmeyer, Executive Director Business Development & Licensing, Novartis Oncology
Anne is a Vice President in Business Development and Licensing in the Oncology Business Unit at Novartis, USA. Her
responsibilities are to in-license or acquire Oncology assets that can further strengthen the Novartis Oncology portfolio. In
this role, she identifies, evaluates, and negotiates transactions for oncology opportunities. She also manages several ongoing
alliances.
Anne has over 15 years of experience in the Pharmaceutical Industry working in positions of increasing responsibilities in
Research, Development, and Business Development and Licensing. Anne joined the Oncology Project Management group of
Novartis in 2004 as a Project Leader. There she led numerous multidisciplinary Project Teams through the generation and
implementation of strategies for various compounds in development and on the market. Before joining Novartis, Anne worked
as a Project Manager at Merck & Co. for close to 4 years and as a Visiting Research Scientist for 2 years.
Anne received her Ph.D. in Molecular Immunology from Strasbourg University, France. She then performed a postdoctoral
fellowship at New York University School of Medicine, USA, and subsequently became a Research Associate at Cornell
University Medical College, New York, USA. In addition to her scientific training, Anne also received a Master in Business
Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, USA.
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS